- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05670821
PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms
Post-marketing Surveillance of Spesolimab I.V. Infusion in Improvement of Generalized Pustular Psoriasis (GPP) With Acute Symptoms in Japan
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Boehringer Ingelheim
- Phone Number: 1-800-243-0127
- Email: clintriage.rdg@boehringer-ingelheim.com
Study Locations
-
-
-
Tokyo, Japan, 1416017
- Recruiting
- Nippon Boehringer Ingelheim Co., Ltd.
-
Contact:
- Yukako Ogi
- Phone Number: +81 (3) 6417 2650
- Email: yukako.ogi@boehringer-ingelheim.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- GPP patients with acute symptoms who are administered Spesolimab Intravenous (I.V.) Infusion in Japan
- Patients who have never been treated with Spesolimab I.V. Infusion before enrolment
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with generalized pustular psoriasis (GPP)
|
Spesolimab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse drug reactions (ADRs)
Time Frame: Up to 36 weeks
|
Incidence of adverse drug reactions (ADRs).
An ADR is defined as a response to a medicinal product which is noxious and unintended.
Response in this context means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility.
Adverse reactions may arise from use of the product within or outside the terms of the marketing authorization or from occupational exposure.
Conditions of use outside the marketing authorization include off-label use, overdose, misuse, abuse and medication errors.
|
Up to 36 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1368-0093
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".
Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Generalized Pustular Psoriasis
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingGeneralized Pustular Psoriasis (GPP)China
-
AbbVieCompletedGeneralized Pustular Psoriasis (GPP) | Adalimumab | Japanese
-
Boehringer IngelheimCompleted
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
CorEvitasRecruitingGeneralized Pustular PsoriasisUnited States
-
Boehringer IngelheimCompletedGeneralized Pustular PsoriasisSpain, Taiwan, Thailand, Korea, Republic of, Germany, Malaysia, United States, Argentina, Belgium, Chile, China, France, Greece, Italy, Japan, Mexico, Netherlands, Philippines, Russian Federation, South Africa, Tunisia, Turkey, Vietnam
-
AnaptysBio, Inc.CompletedGeneralized Pustular PsoriasisUnited States, Australia, Georgia, Germany, Korea, Republic of, Malaysia, Morocco, Poland, Romania, Spain, Taiwan, Thailand, Tunisia, Turkey, Slovakia
-
Boehringer IngelheimCompletedPsoriasisTaiwan, Malaysia, France, Japan, Korea, Republic of, Tunisia
Clinical Trials on Spesolimab
-
Icahn School of Medicine at Mount SinaiBoehringer IngelheimRecruiting
-
Boehringer IngelheimRecruitingHidradenitis SuppurativaUnited States, Korea, Republic of, Israel, Spain, Australia, Japan, Italy, Germany, Belgium, Lithuania, China, Canada, Malaysia, Singapore, New Zealand, France, Mexico, Netherlands, United Kingdom, Denmark, Bulgaria, Philippines, Vi... and more
-
Boehringer IngelheimTerminatedFibrostenotic Crohn´s DiseaseUnited States, Canada, Japan, Sweden
-
Boehringer IngelheimCompletedPalmoplantar Pustulosis (PPP)United Kingdom, Korea, Republic of, United States, Canada, Belgium, Australia, Taiwan, Japan, France, Germany, Russian Federation, Hungary, Netherlands, Czechia, Poland
-
Boehringer IngelheimCompletedPsoriasisSpain, Denmark, Germany, Canada, Sweden, Italy
-
Boehringer IngelheimRecruiting
-
Boehringer IngelheimTerminatedPalmoplantar PustulosisUnited Kingdom, Korea, Republic of, United States, Canada, Belgium, Australia, Taiwan, Japan, France, Germany, Russian Federation, Czechia, Hungary, Poland
-
Boehringer IngelheimActive, not recruitingHidradenitis SuppurativaAustralia, United States, Germany, Netherlands, Italy, Canada, Czechia, France, Norway, Poland, Spain
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedColitis, UlcerativeBelgium, Germany, United Kingdom